



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

May 27,2025

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting held on May 27,2025**

We are pleased to inform you that a meeting of the Board of Directors of the Company held today (commenced at 5:17 pm and ended at 5.47 pm), the Audited Financial Results for the Financial Year ended March 31,2025 were approved.

We are enclosing herewith the following:

- Audited Financial Results for the Financial Year ended March 31,2025, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
- Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
- A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a final dividend of Rs. 65 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended March 31,2025. The dividend shall be paid between August 27, 2025 to September 23, 2025, on approval of the Members at the 61<sup>st</sup> Annual General Meeting.

Further, the Board of Directors today, have also approved, appointment of M/s. M K Saraf & Associates LLP, Practising Company Secretaries (Firm Registration Number: L2025MH018600),peer reviewed firm (having Peer Review Certificate No.6694/2025), as the Secretarial Auditors for a term of five consecutive years commencing from April 1, 2025 till March 31, 2030, on the approval of members at the ensuing Annual General Meeting. The brief profile of M/s. M K Saraf & Associates LLP is enclosed below.

Kindly take the same on record. Thanking you.

For **Procter & Gamble Hygiene and Health Care Limited**

**Ghanashyam Hegde**  
**Director & Company Secretary**



Procter & Gamble Hygiene  
and Health Care Limited  
CIN: L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91 - 22) 6958 6000  
Fax: (91 - 22) 6958 7337  
Website: in.pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH PERIOD ENDED 31st MARCH 2025

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2025 (Audited) (Refer Note 13 below)	Preceding Three Months Ended 31st December 2024 (Unaudited)	Corresponding Three Months Ended 31st March 2024 (Unaudited)	Nine Months Ended 31st March 2025 (Audited) (Refer Note 5 below)	Corresponding Nine Months Ended 31st March 2024 (Unaudited)	Previous Year Ended 30th June 2024 (Audited)
<b>1 Income</b>						
Sale of products	98 913	1 24 625	99 815	3 36 811	3 26 414	4 19 157
Other operating revenues	250	138	402	631	981	1 413
<b>2 Revenue from operations</b>	<b>99 163</b>	<b>1 24 763</b>	<b>1 00 217</b>	<b>3 37 442</b>	<b>3 27 395</b>	<b>4 20 570</b>
<b>3 Other income</b>	<b>1 913</b>	<b>971</b>	<b>1 359</b>	<b>3 734</b>	<b>4 494</b>	<b>5 225</b>
<b>Total income (2+3)</b>	<b>1 01 076</b>	<b>1 25 734</b>	<b>1 01 576</b>	<b>3 41 176</b>	<b>3 31 889</b>	<b>4 25 795</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	17 540	19 782	16 400	56 722	59 509	77 194
b) Purchases of stock-in-trade (Traded goods)	21 003	24 604	18 086	67 289	62 258	85 438
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	930	( 471)	( 710)	1 500	1 617	( 1 213)
d) Employee benefits expense	4 937	6 617	6 009	17 605	17 851	24 564
e) Finance costs	577	662	2 247	1 430	2 702	2 700
f) Depreciation and amortization expense	1 035	989	1 454	3 194	4 310	5 650
g) Impairment losses (Refer Note 8)	----	----	----	----	----	1 303
h) Advertising & sales promotion expenses	12 116	15 834	13 404	45 244	41 410	56 775
i) Other expenses	21 672	21 304	21 262	61 676	59 540	79 484
<b>Total expenses</b>	<b>79 810</b>	<b>89 321</b>	<b>78 182</b>	<b>2 54 960</b>	<b>2 49 197</b>	<b>3 31 875</b>
<b>5 Profit before tax (2+3-4)</b>	<b>21 266</b>	<b>36 413</b>	<b>23 394</b>	<b>86 216</b>	<b>82 692</b>	<b>93 920</b>
<b>6 Income tax expense</b>						
a) Current tax	5 167	6 974	6 967	22 136	22 663	25 955
b) Deferred tax	( 24)	423	( 820)	( 249)	( 1 419)	( 1 586)
c) Prior year tax adjustments	513	157	1 810	670	2 052	2 049
	<b>5 656</b>	<b>9 554</b>	<b>7 957</b>	<b>22 557</b>	<b>23 296</b>	<b>26 418</b>
<b>7 Profit for the period / year (5-6)</b>	<b>15 610</b>	<b>26 859</b>	<b>15 437</b>	<b>63 659</b>	<b>59 396</b>	<b>67 502</b>
<b>8 Other comprehensive income / (loss)</b>						
Items that will not be reclassified to profit or loss:						
Remeasurement of the defined benefit plans	( 258)	( 870)	429	( 943)	924	738
Income tax effect on above	65	218	( 108)	237	( 233)	( 186)
<b>Total other comprehensive income / (loss) for the period</b>	<b>( 193)</b>	<b>( 652)</b>	<b>321</b>	<b>( 706)</b>	<b>691</b>	<b>552</b>
<b>9 Total comprehensive income for the period / year (7+8)</b>	<b>15 417</b>	<b>26 207</b>	<b>15 758</b>	<b>62 953</b>	<b>60 087</b>	<b>68 054</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>				<b>70 453</b>		<b>74 240</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised):</b>						
a) Basic	48.09	82.74	47.56	196.11	182.98	207.95
b) Diluted	48.09	82.74	47.56	196.11	182.98	207.95

See accompanying notes to the financial results

Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	31st March 2025 (Audited)	30th June 2024 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	13 137	13 916
Capital work-in-progress	4 071	2 775
<b>Financial assets</b>		
(i) Loans	3 862	3 146
(ii) Other financial assets	434	955
Deferred tax assets (Net)	8 242	7 487
Non-current tax assets (Net)	23 043	25 019
Other non-current assets	12 002	11 690
<b>Total non-current assets</b>	<b>64 791</b>	<b>65 888</b>
<b>Current assets</b>		
Inventories	22 140	22 556
<b>Financial assets</b>		
(i) Trade receivables	30 410	24 083
(ii) Cash and cash equivalents	46 637	57 367
(iii) Bank balances other than (ii) above	1 433	1 453
(iv) Loans	463	389
(v) Other financial assets	3 513	8 024
Other current assets	4 467	5 106
	1 09 063	1 19 968
Non current assets held for sale	1 619	---
<b>Total current assets</b>	<b>1 10 682</b>	<b>1 19 968</b>
<b>Total Assets</b>	<b>1 75 473</b>	<b>1 85 856</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	70 453	74 240
<b>Total Equity</b>	<b>73 699</b>	<b>77 486</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	1	1
Provisions	11 667	10 303
<b>Total non-current liabilities</b>	<b>11 668</b>	<b>10 304</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	231	307
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	754	717
Total outstanding dues of creditors other than micro enterprises and small enterprises	80 188	84 448
(iii) Other financial liabilities	1 929	3 185
Other current liabilities	5 707	4 791
Provisions	1 297	1 055
Current tax liabilities (net)	---	3 583
<b>Total current liabilities</b>	<b>90 106</b>	<b>98 066</b>
<b>Total Liabilities</b>	<b>1 01 774</b>	<b>1 08 370</b>
<b>Total Equity and Liabilities</b>	<b>1 75 473</b>	<b>1 85 856</b>

## 2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Nine Month Period Ended	Previous Year Ended
	31 <sup>st</sup> March 2025 (Audited)	30 <sup>th</sup> June 2024 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	86 216	93 920
Adjustments for:		
Depreciation and amortization expense	3 194	5 650
Loss on disposal of property, plant and equipment	23	554
Finance costs	1 414	2 678
Allowance for doubtful receivables (Net of recovery)	311	99
Interest income	( 2 778)	( 4 399)
Impairment losses	---	1 303
Net foreign exchange loss	27	158
Inventory written off (net of Insurance claims recovered)	997	1 281
Provisions no longer required written back	( 673)	( 894)
Expense recognised in respect of equity settled share based payments	612	850
<b>Operating profit before working capital changes</b>	<b>89 345</b>	<b>1 01 380</b>
Working capital adjustments		
(Increase) in trade and other receivables	( 6 568)	( 2 554)
Decrease / (Increase) in financial assets	5 171	( 6 158)
(Increase) in inventories	( 581)	( 1 837)
Decrease / (Increase) in other assets	388	( 2 309)
(Decrease) in trade and other payables	( 4 236)	( 11 600)
Increase / (Decrease) in provisions	108	( 158)
<b>Cash generated from operations</b>	<b>83 627</b>	<b>76 768</b>
Income taxes paid (net of refund)	( 24 306)	( 29 766)
<b>Net cash generated from operating activities</b>	<b>59 321</b>	<b>47 002</b>
<b>B. Cash Flows from Investing Activities</b>		
Loan given to related parties	---	( 70 000)
Loan repaid by related parties	---	70 000
Interest received	2 435	4 433
Payment to acquire property, plant and equipment and capital work-in-progress	( 5 503)	( 4 468)
Proceeds from sale of property, plant and equipment	41	141
Net bank deposits (placed)	( 1)	---
Changes in earmarked balances	( 400)	---
<b>Net cash (used in) / generated from investing activities</b>	<b>( 3 428)</b>	<b>106</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend paid	( 66 545)	( 88 021)
Principal payment of lease liabilities	( 76)	( 95)
Interest paid on lease liabilities	( 2)	( 8)
<b>Net cash (used in) financing activities</b>	<b>( 66 623)</b>	<b>( 88 124)</b>
<b>Net (Decrease) in cash and cash equivalents ( A + B + C )</b>	<b>( 10 730)</b>	<b>( 39 016)</b>
Cash and cash equivalents at the beginning of the year	57 367	96 383
<b>Cash and cash equivalents at the end of the period / year</b>	<b>46 637</b>	<b>57 367</b>

- 3 The above audited financial results for the quarter and nine month period ended March 31, 2025, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 27, 2025. These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 These Financial Results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), as amended, prescribed under Section 133 of the Companies Act 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- 5 The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the current Financial Year of the Company viz., 2024-25 shall be for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year.
- 6 The Board of Directors at its meeting held on May 27, 2025, have recommended a payment of final dividend of ₹ 65 per equity share of face value ₹10 each aggregating to ₹ 21 099 lakhs.
- 7 During the previous year, the Company had arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the years ended March 2011 to March 2019. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 656 lakhs, and interest amounting to ₹ 1 944 lakhs, had been accounted as Prior Period Tax Adjustments and Finance Costs respectively in the previous year.
- 8 During the previous year, certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at June 30, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, had been tested for impairment and an impairment loss amounting to ₹ 1,303 lakhs had been recognized in the financial results for the year ended June 30, 2024. During the current period, the Company has reassessed the impairment recognised based on an "Agreement to Sell" entered into with a buyer and has reversed the excess provision for impairment loss of ₹ 673 lakhs under "Other Income". The Company has now recorded these items of Property, Plant & Equipment amounting to ₹ 1,619 lakhs as Non Current Assets held for sale.
- 9 The Company's operating segments under Ind AS 108 – Operating Segments are as follows:  
- Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets  
- Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene  
These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided.
- 10 The Company does not have a subsidiary, associate or a joint venture as at March 31, 2025.
- 11 The Statement of Assets and Liabilities as at March 31, 2025, is attached therewith as Note 1.
- 12 The Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS -7 on the "Statement of Cash Flows" and is attached herewith as Note 2.
- 13 The figures for the last quarter ended March 31, 2025, are the balancing figures between the audited figures in respect of the nine month period ended March 31, 2025 and the published unaudited year to date figures upto the end of the second quarter ended December 31, 2024.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

  
Kumar Venkatasubramanian  
Managing Director

Place: Mumbai  
Date: May 27, 2025





Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91 - 22) 6958 8000  
Fax: (91 - 22) 6958 7337  
Website in pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH PERIOD ENDED 31st MARCH 2025

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2025 (Audited) (Refer Note 13 below)	Preceding Three Months Ended 31st December 2024 (Unaudited)	Corresponding Three Months Ended 31st March 2024 (Unaudited)	Nine Months Ended 31st March 2025 (Audited) (Refer Note 5 below)	Corresponding Nine Months Ended 31st March 2024 (Unaudited)	Previous Year Ended 30th June 2024 (Audited)
<b>1 Income</b>						
Sale of products	98 913	1 24 625	99 815	3 36 811	3 26 414	4 19 157
Other operating revenues	250	138	402	631	981	1 413
<b>2 Revenue from operations</b>	<b>99 163</b>	<b>1 24 763</b>	<b>1 00 217</b>	<b>3 37 442</b>	<b>3 27 395</b>	<b>4 20 570</b>
3 Other income	1 913	971	1 359	3 734	4 494	5 225
<b>Total income (2+3)</b>	<b>1 01 076</b>	<b>1 25 734</b>	<b>1 01 576</b>	<b>3 41 176</b>	<b>3 31 889</b>	<b>4 25 795</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	17 540	19 782	16 400	56 722	59 509	77 194
b) Purchases of stock-in-trade (Traded goods)	21 003	24 604	18 086	67 289	62 258	85 438
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	930	( 471)	( 710)	1 500	1 617	( 1 213)
d) Employee benefits expense	4 937	6 617	6 009	17 605	17 851	24 584
e) Finance costs	577	662	2 247	1 430	2 702	2 700
f) Depreciation and amortization expense	1 035	989	1 454	3 194	4 310	5 650
g) Impairment losses (Refer Note 8)	---	---	---	---	---	1 303
h) Advertising & sales promotion expenses	12 116	15 834	13 404	45 244	41 410	58 775
i) Other expenses	21 672	21 304	21 292	61 976	59 540	79 464
<b>Total expenses</b>	<b>79 810</b>	<b>89 321</b>	<b>78 182</b>	<b>2 54 960</b>	<b>2 49 197</b>	<b>3 31 875</b>
<b>5 Profit before tax (2+3-4)</b>	<b>21 266</b>	<b>36 413</b>	<b>23 394</b>	<b>86 216</b>	<b>82 692</b>	<b>93 920</b>
<b>6 Income tax expense</b>						
a) Current tax	5 167	8 974	6 967	22 136	22 663	25 955
b) Deferred tax	( 24)	423	( 820)	( 249)	( 1 419)	( 1 586)
c) Prior year tax adjustments	513	157	1 810	670	2 052	2 049
	<b>5 656</b>	<b>9 554</b>	<b>7 957</b>	<b>22 557</b>	<b>23 296</b>	<b>26 418</b>
<b>7 Profit for the period / year (5-6)</b>	<b>15 610</b>	<b>26 859</b>	<b>15 437</b>	<b>63 659</b>	<b>59 396</b>	<b>67 502</b>
<b>8 Other comprehensive income / (loss)</b>						
Items that will not be reclassified to profit or loss.						
Remeasurement of the defined benefit plans	( 258)	( 870)	429	( 943)	924	738
Income tax effect on above	65	218	( 108)	237	( 233)	( 186)
<b>Total other comprehensive income / (loss) for the period</b>	<b>( 193)</b>	<b>( 652)</b>	<b>321</b>	<b>( 706)</b>	<b>691</b>	<b>552</b>
<b>9 Total comprehensive income for the period / year (7+8)</b>	<b>15 417</b>	<b>26 207</b>	<b>15 758</b>	<b>62 953</b>	<b>60 087</b>	<b>68 054</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>				<b>70453</b>		<b>74 240</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	48.09	82.74	47.56	196.11	182.98	207.95
b) Diluted	48.09	82.74	47.56	196.11	182.98	207.95

See accompanying notes to the financial results



Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	31st March 2025 (Audited)	30th June 2024 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	13 137	13 918
Capital work-in-progress	4 071	2 775
<b>Financial assets</b>		
(i) Loans	3 882	3 148
(ii) Other financial assets	434	955
Deferred tax assets (Net)	8 242	7 487
Non-current tax assets (Net)	23 043	25 919
Other non-current assets	12 002	11 690
<b>Total non-current assets</b>	<b>64 791</b>	<b>65 888</b>
<b>Current assets</b>		
Inventories	22 140	22 556
<b>Financial assets</b>		
(i) Trade receivables	30 410	24 083
(ii) Cash and cash equivalents	46 837	57 367
(iii) Bank balances other than (ii) above	1 433	1 453
(iv) Loans	463	389
(v) Other financial assets	3 513	8 924
Other current assets	4 487	5 198
	1 09 063	1 19 968
Non current assets held for sale	1 619	---
<b>Total current assets</b>	<b>1 10 682</b>	<b>1 19 968</b>
<b>Total Assets</b>	<b>1 75 473</b>	<b>1 85 856</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	70 453	74 240
<b>Total Equity</b>	<b>73 699</b>	<b>77 486</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	1	1
Provisions	11 667	10 303
<b>Total non-current liabilities</b>	<b>11 668</b>	<b>10 304</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Lease liabilities	231	307
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	754	717
Total outstanding dues of creditors other than micro enterprises and small enterprises	80 188	84 448
(iii) Other financial liabilities	1 929	3 185
Other current liabilities	5 707	4 791
Provisions	1 297	1 055
Current tax liabilities (net)	---	3 583
<b>Total current liabilities</b>	<b>90 106</b>	<b>98 066</b>
<b>Total Liabilities</b>	<b>1 01 774</b>	<b>1 08 370</b>
<b>Total Equity and Liabilities</b>	<b>1 75 473</b>	<b>1 85 856</b>



## 2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Nine Month Period Ended	Previous Year Ended
	31 <sup>st</sup> March 2025 (Audited)	30 <sup>th</sup> June 2024 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	86 216	93 920
Adjustments for:		
Depreciation and amortization expense	3 194	5 650
Loss on disposal of property, plant and equipment	23	554
Finance costs	1 414	2 678
Allowance for doubtful receivables (Net of recovery)	311	99
Interest income	( 2 778)	( 4 399)
Impairment losses	---	1 303
Net foreign exchange loss	27	158
Inventory written off (net of Insurance claims recovered)	997	1 281
Provisions no longer required written back	( 673)	( 694)
Expense recognised in respect of equity settled share based payments	612	850
<b>Operating profit before working capital changes</b>	<b>89 345</b>	<b>1 01 380</b>
Working capital adjustments		
(Increase) in trade and other receivables	( 6 566)	( 2 554)
Decrease / (Increase) in financial assets	5 171	( 6 156)
(Increase) in inventories	( 581)	( 1 837)
Decrease / (Increase) in other assets	388	( 2 309)
(Decrease) in trade and other payables	( 4 236)	( 11 600)
Increase / (Decrease) in provisions	106	( 156)
<b>Cash generated from operations</b>	<b>83 627</b>	<b>76 768</b>
Income taxes paid (net of refund)	( 24 306)	( 29 766)
<b>Net cash generated from operating activities</b>	<b>59 321</b>	<b>47 002</b>
<b>B. Cash Flows from Investing Activities</b>		
Loan given to related parties	---	( 70 000)
Loan repaid by related parties	---	70 000
Interest received	2 435	4 433
Payment to acquire property, plant and equipment and capital work-in-progress	( 5 503)	( 4 468)
Proceeds from sale of property, plant and equipment	41	141
Net bank deposits (placed)	( 1)	---
Changes in earmarked balances	( 400)	---
<b>Net cash (used in) / generated from investing activities</b>	<b>( 3 428)</b>	<b>106</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend paid	( 66 545)	( 86 021)
Principal payment of lease liabilities	( 76)	( 95)
Interest paid on lease liabilities	( 2)	( 8)
<b>Net cash (used in) financing activities</b>	<b>( 66 623)</b>	<b>( 86 124)</b>
<b>Net (Decrease) in cash and cash equivalents ( A + B + C )</b>	<b>( 10 730)</b>	<b>( 39 016)</b>
Cash and cash equivalents at the beginning of the year	57 367	96 383
<b>Cash and cash equivalents at the end of the period / year</b>	<b>46 637</b>	<b>57 367</b>

- 3 The above audited financial results for the quarter and nine month period ended March 31, 2025, have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 27, 2025. These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 These Financial Results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), as amended, prescribed under Section 133 of the Companies Act 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- 5 The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the current Financial Year of the Company viz., 2024-25 shall be for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year.
- 6 The Board of Directors at its meeting held on May 27, 2025, have recommended a payment of final dividend of ₹ 65 per equity share of face value ₹ 10 each aggregating to ₹ 21 099 lakhs.
- 7 During the previous year, the Company had arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the years ended March 2011 to March 2019. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 656 lakhs, and interest amounting to ₹ 1 944 lakhs, had been accounted as Prior Period Tax Adjustments and Finance Costs respectively in the previous year.
- 8 During the previous year, certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at June 30, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, had been tested for impairment and an impairment loss amounting to ₹ 1,303 lakhs had been recognized in the financial results for the year ended June 30, 2024. During the current period, the Company has reassessed the impairment recognised based on an "Agreement to Sell" entered into with a buyer and has reversed the excess provision for impairment loss of ₹ 673 lakhs under "Other Income". The Company has now recorded these items of Property, Plant & Equipment amounting to ₹ 1.619 lakhs as Non Current Assets held for sale.
- 9 The Company's operating segments under Ind AS 108 – Operating Segments are as follows  
- Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets  
- Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene  
These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided.
- 10 The Company does not have a subsidiary, associate or a joint venture as at March 31, 2025.
- 11 The Statement of Assets and Liabilities as at March 31, 2025, is attached therewith as Note 1.
- 12 The Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS -7 on the "Statement of Cash Flows" and is attached herewith as Note 2.
- 13 The figures for the last quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the nine month period ended March 31, 2025 and the published unaudited year to date figures upto the end of the second quarter ended December 31, 2024.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

  
Kumar Venkatasubramanian  
Managing Director



Place: Mumbai  
Date: May 27, 2025



# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

## **INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS**

**PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

### **Report on the Audit of the Financial Results**

#### **Opinion**

We have audited the accompanying Statement of Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter and nine month period ended March 31, 2025, together with the notes thereon, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the nine month period ended March 31, 2025.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Management's Responsibilities for the Financial Results**

These quarterly and nine month period ended Financial Results have been prepared on the basis of the nine month period financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.


**Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

The Board of Directors of the Company have, vide a circular resolution dated January 23, 2025, resolved to change the financial year end from June 30 to March 31. Accordingly, the financial results for the current financial year of the Company as per the provisions of section 2(41) of the Companies Act, 2013, is for a period of nine months from July 1, 2024, to March 31, 2025. Further, as the said financial results are only for a period of nine months, the same are not comparable to the audited financial results for the previous financial year ended June 30, 2024.

The financial results include the results for the quarter ended March 31, 2025, being the balancing figures between the audited figures in respect of the nine months ended March 31, 2025, and the published unaudited year to date figures up to the end of the second quarter which were subjected to limited review by us.

Our opinion on the Financial Results is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS**

Firm Regn. No.: 104607W / W100166

  
*Daraius Z. Fraser*  
**PARTNER**

M. No.: 042454

UDIN: 25042454BMOEWA8683

Mumbai: May 27, 2025.



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

May 27,2025

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir/Madam,

**Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited  
Financial Results for the Financial Year ended March 31,2025**

We hereby declare that Audited Financial Results for the Financial Year ended March 31,2025, 2024 which have been approved by the Board of Directors of the Company at meeting held today, i.e., May 27,2025, the Statutory Auditors, Kalyaniwalla & Mistry LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Yours faithfully,

**For Procter & Gamble Hygiene and Health Care Limited**

**Ghanashyam Hegde**  
**Director & Company Secretary**



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 6958 6000  
Fax: (91-22) 6958 7337  
Website: in.pg.com

**Appointment of M/s M K Saraf & Associates LLP, Practising Company Secretaries as Secretarial Auditors of the Company for the term of 5 consecutive years as per the provisions of SEBI LODR Regulations,2015.**

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024, are provided below:

<b>Particulars</b>	<b>Details</b>
<b>Reason for Change viz. Appointment</b>	Appointment of M/s. M K Saraf & Associates LLP, Practising Company Secretaries (Firm Registration Number: L2025MH018600), peer reviewed firm (having Peer Review Certificate No.6694/2025), as the Secretarial Auditors for a term of five consecutive years commencing from April 1, 2025 till March 31, 2030
<b>Date of appointment and term of appointment</b>	Five consecutive years commencing from April 1, 2025 till March 31, 2030. (From FY 2025- 26 till FY 2029-30)
<b>Brief Profile</b>	<p>M/s. M K Saraf &amp; Associates LLP (Firm Registration Number: L2025MH018600) is a leading firm of practicing Company Secretaries. Specialization of the firm includes, but is not limited to, Secretarial, Corporate law and banking law related services including incorporation services, Corporate Governance, Capital markets, RBI, etc. The firm has been peer reviewed in terms of the guidelines issued by ICSI.</p> <p>This LLP has been founded in 2025, with a vision to grow in scope and depth by integrating new expertise over time, while carrying forward a legacy of over 30 years built on excellence, trust, and integrity, by Mr. K. G. Saraf, designated partner, a qualified Company Secretary, who laid the foundation of his own practice in 1989 under the name Saraf &amp; Associates, Company Secretaries, serving reputed clients and Mr. Mandar Saraf, designated partner, who with over a decade of experience in corporate laws and compliance audits, brings valuable insight and a fresh perspective to the profession.</p>
<b>Disclosure of relationships between directors (in case of appointment of a director)</b>	Not Applicable